Gene electrotransfer: Potential for gene therapy of renal diseases  by Imai, Enyu & Isaka, Yoshitaka
Kidney International, Vol. 61, Symposium 1 (2002), pp. S37–S41
Gene electrotransfer: Potential for gene therapy of
renal diseases
ENYU IMAI and YOSHITAKA ISAKA
Department of Internal Medicine and Therapeutics, Division of Nephrology, Osaka University Graduate School
of Medicine, Osaka, Japan
Gene electrotransfer: Potential for gene therapy of renal dis- plasma membrane [4–6]. The electric breakdown of the
eases. The ability to pursue gene therapy has been limited by membrane can be achieved by high field strength. Elec-
the availability of an effective and safe system for gene delivery, troporation, which is defined as pore formation followingespecially to the kidney. Electroporation is an efficient method
the electric breakdown, has been applied to gene transferto transfer physiologically the gene to the cells without compli-
to cells and organs without complicated preparation. Thecated preparation. Given that the systemic delivery of the func-
tional protein can serve for the therapy of the renal diseases, use of the technique was initially limited to suspensions
skeletal muscle targeting gene therapy might be an alternative of cultured cells. Recently, several techniques were de-
strategy for treatment of renal disease. Gene therapy to the
veloped for in vivo gene transfer. Skeletal muscle is onetransplant kidney may potentially improve the graft outcome
of the most promising tissues to introduce the foreignby reducing acute and chronic rejections. We review on an
emerging strategy of gene electrotransfer and discuss the poten- genes by electroporation. Given that the systemic deliv-
tial application of gene therapy to renal diseases. ery of the functional protein can serve for the therapy of
the renal diseases, skeletal muscle targeting gene therapy
might be an alternative strategy for treatment of renal
Gene therapy has a distinct potential to treat disease disease [7]. Furthermore, we developed a new strategy
by innovative strategies. We can supply the necessary to apply electroporation to gene transfer to the kidney
gene product by gene transfer to patients. The transgene in vivo [8]. We review an emerging strategy of gene
can continuously provide an active molecule or a specific electrotransfer to kidney and discuss the potential appli-
inhibitory protein to patients. Furthermore, we can cure cation to the therapy of renal diseases.
the patient at the fundamental level by replacing the
mutated gene with the correct one. The ability to pursue
MECHANISM OF ELECTROPORATIONgene therapy, however, has been limited by the availabil-
ity of an adequate system for gene delivery, particularly An electric field causes cell fusion and an increase in
to the kidney [1]. The current viral vector systems seem membrane permeability. In 1965, Coster reported a phe-
to have restricted clinical use for targeting kidney. Ade- nomenon of “punch-through” of the membrane by an
noviral vectors cannot currently be employed for human electric field [9]. In 1973, Zimmermann et al described
gene therapy because of the risk of toxicity and immuno- a reversal electrical breakdown of cell membrane [10].
genisity. Retroviral vectors, in which proliferation is pre- They discharged electric pulses to an E. coli suspension
requisite for integration into the genome, do not meet in a chamber and analyzed size fractionation of E. coli.
kidney–targeting gene transfers requirements. Nonviral They found a reduction of the volume of E. coli if critical
vectors mediated gene transfer methods such as cationic field strength is exceeded, suggesting that the cell mem-
liposome [2], and the hemagglutinating virus of Japan brane was breaking down. Zimmmerman summarized
(HVJ) liposome-mediated gene transfer method [1, 3] data and ideas and proposed a mechanism of electrical
may be promising but need to be improved in efficacy. breakdown of the cell membrane in vitro [4]. The mem-
It is well established that the electric field induces fu- brane becomes extremely conductive, and the current
sion of cell membranes and changes permeability of lines pass through the inside of the cell according to the
increase in field strength (Fig. 1). Consequently, pore
formation by electrical breakdown, electroporation, is
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accomplished. The pore formation is a very rapid event,factor-, hepatocyte growth factor, electroporation, kidney transplanta-
tion, chronic rejection. occurring within 10 ns [11]. The size of electric pore was
estimated to be less than 10 nm [12, 13]. With increasing 2002 by the International Society of Nephrology
S-37
Imai and Isaka: Gene electrotransferS-38
Fig. 1. Possible mechanisms of DNA transfer
by electroporation. (A) The membrane be-
comes extremely conductive, and the current
lines pass through the inside of the cell when
the electric field is intensified to certain limit.
Pore formation by electrical breakdown, elec-
troporation, is accomplished (top). Only the
DNA bound to the membrane is transferred
to the inside (bottom). Some mechanism to
move the DNA toward the pore has been
suggested.
duration of the electric field, the number of pores is poration for gene transfer in vitro [18]. They transfected
herpes simplex thymisine kinase gene into mouse fibro-increasing, and they merge. When the pores merge into
one large pore, irreversible breakdown occurs. The re- blast L cells at 8 kV/cm for 5 ms. Since that time, various
closing of the membrane can be delayed by keeping the animal cells have been transfected by electroporation,
cells at low temperature. Theoretically, if the molecule including myeloma cells, neuronal cells, lymphocytes,
is smaller than pore size, for example, oligonucleotide endocrine cells, hepatoma cells, and hematopoietic stem
and chemical compounds, they can be transferred into cells [19–24]. Generally, the cells were treated with con-
the cytosol of the cells. However, the maximum size of ditions including 15 kV and capacitance of 25 F in a
the DNA molecule that can be introduced by electropor- chamber. After electroporation, the exogenous DNA
ation is at least 150 kb [14]. If the mechanism of gene can be present in cytoplasm and nucleus.
transfer is simply explained by diffusion, the 10 nm pore Exogenous DNA is transcribed in the nucleus in a
can hardly transfer the large size DNA. Mir et al investi- transient fashion and, at a lower frequency, integrated
gated the mechanism of in vivo gene transfer by compar- in the genome. The incidence of mutation by electric
ing LacZ gene expression and the uptake of 51Cr-EDTA, gene transfer might be lower than by CaPO4 or diethyl-
a marker of small molecule uptake in muscle-fiber per- aminoethyl (DEAE) dextran coprecipitation [25].
meabilitzation [15]. They observed uptake of 51Cr-EDTA
by the skeletal muscle even if 51Cr-EDTA was adminis-
APPLICATION OF ELECTROPORATION TOtrated 30 seconds after an electric pulse, whereas the
IN VIVO GENE TRANSFERLacZ gene expression was observed only when LacZ
Electroporation has been applied to gene transfer ingene was administered before an electric pulse. These
vivo since 1991. However, the molecular mechanism lead-results suggests that the instability of lipid bilayer may
ing to pore formation following electrical breakdown ispersist for a while after the electric pulse and that there
obscure in vivo. Electroporation can be achieved locallyare different mechanisms of DNA and 51Cr-EDTA trans-
in vivo by insertion of electrodes into the tissue or byfer to the muscle by electric field. In addition, Cherno-
holding the tissue with plate type electrodes. A relevantmordik et al proposed that DNA is taken up by lipid
clinical application, electrochemotherapy, is being pur-vesicles and is enclosed by a shell of lipids by electropora-
sued in oncology by using cell electropermeabilizationtion [16]. Xie et al demonstrated that only the DNA
to allow the cellular entry of hydrophilic anticancer agentsbound to the membrane is able to transfect E. coli after
[26]. A short (less than 100 s) and high-voltage electricelectric pulse treatment [17]. Two plausible mechanisms
pulse (250 V) was used for electrochemotherapy, andof DNA transfection by electric field are depicted in
this approach resulted in a drastically increased antitu-Figure 1. Taken together, it is suggested that the electric
mor effect of bleomycin. Titomirov et al first transfectedfield increases gene transfer not only by membrane per-
DNA to skin by electroporation [27]. Several reportsmeabilization but also by a direct effect on the DNA
have been published demonstrating the efficacy and re-molecule, promoting migration and cellular uptake.
Neumann et al first reported the application of electro- producibility of in vivo electroporation in various tissues
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Fig. 1. (Continued). (B) The electric pulse
causes membrane instability (top). The insta-
bility of the lipid bilayer results in formation
of vesicles containing DNA. The DNA in-
cluded in the lipid vesicles is endocytosed, and
the DNA is transferred to cytosol (bottom).
Table 1. Reported approaches in vivo gene transfer by electroporation
Species Tissue Electric field Transfectant Duration of expression Reference
Mouse Muscle 100 V, 50 ms6 IL-5 9 months [28]
Mouse Muscle 200V, 20 ms  8 Luciferase 9 months [15]
Mouse Muscle 25–45 V, 100 ms2000 LacZ, luciferase 4 weeks [32]
Mouse Muscle 900 V, 100 ms5 LacZ, luciferase 6 months [31]
Mouse Muscle 45 V, 200 ms1000 Erythropoietin 100 days [30]
Rat Muscle 45 V, 200 ms1000 Erythropoietin 300 days [29]
Mouse Muscle 100 V, 50 ms6 IFN-r-R/Fc ND [41]
Rat Muscle 100 V, 50 ms6 PDGF-R/Fc 8 weeks [42]
Mouse Skin 400 V, 100 ms CAT 4 weeks [27]
Rat Liver 1000 V/cm, 99 ms LacZ 3 weeks [34]
Rat Liver 50 V, 50 ms8 GFP ND [35]
Mouse Testis 50 V, 10 ms8 CAT, LacZ ND [36]
Rat Kidney 75 V, 50 ms6 LacZ, luciferase 8 weeks [8]
(Table 1). Among them, skeletal muscle targeting gene matrix expansion of anti-Thy1 glomerulonephritis. They
transfer has been extensively studied [28–32]. Most of used a proteoglycan, decorin [40], and a soluble receptor
the studies were performed by using square pulses of for TGF-, which is composed of extracellular domain
short (100 to 300 ms) duration at 100 to 400 V, and the of TGF- type II receptor and IgG-Fc (TGF-RII/Fc)
transgene product was detectable in the serum for at [41]. Decorin and the soluble receptor TGF-RII/Fc
most 9 months [28]. Skin [27, 33], liver [34, 35], testis bind to active TGF-, resulting in its inactivation. A
[36], melanoma [37], and solid tumor [38, 39] can be plasmid encoding TGF-RII/Fc cDNA was transfected
transfected by electroporation with similar electric field into skeletal muscle by electroporation and synthesized
condition. soluble receptor accumulated in glomeruli (unpublished
observation). Interestingly, the increment in extracellu-
lar matrix in nephritic rats was reduced in proportion toSKELETAL MUSCLE-TARGETING GENE
the decrease of TGF- mRNA. These results suggestTHERAPY FOR KIDNEY DISEASE
that manipulation of overexpressed TGF- by skeletalAs discussed previously in this article, gene delivery
muscle targeting gene therapy may ameliorate the pro-to skeletal muscle is a promising strategy for the systemic
gression of glomerulonephritis.delivery of a therapeutic protein [7]. Application of the
Mesangial cell proliferation and phenotypic altera-strategy to intervention for experimental glomerulo-
tion occur in an early phase of glomerular injury andnephritis has been attempted. Recently, Isaka et al proved
precede increased extracellular matrix accumulation. Athat the intervention of overexpressed transforming
growth factor- (TGF-) ameliorates the extracellular critical growth factor responsible for mesangial prolifera-
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tion is platelet-derived growth factor (PDGF), which is kidneys except small burns on the surface of kidney in
contact with electrodes. The burn injury became promi-a potent mitogen. We generated a chimeric cDNA en-
coding an extracellular domain of the -PDGF receptor nent at 100 V. There was no histological damage in
glomeruli and tubular epithelial cells by electric pulsesfused with IgG-Fc, termed PDGFR/Fc, and examined
the feasibility of gene therapy targeting PDGF using even at 75 V. Comparing in vivo transfection efficacy of
electroporation with that of HVJ liposome method, thePDGFR/Fc [42]. The chimeric PDGFR/Fc molecule
completely inhibited the tyrosine phosphorylation of electroporation-mediated gene transfer technique re-
sulted in a 10-fold higher glomerular luciferase activity-PDGF receptors and cellular proliferation induced by
PDGF in vitro. We then introduced the PDGFR/Fc ex- than the HVJ liposome method [8]. Thus, in vivo gene
electrotransfer targeting kidney is an effective methodpression vector into the muscle of nephritic rats by elec-
troporation. The chimeric PDGFR/Fc concentration in for gene transfer and can provide a new technique for
kidney targeting gene therapy.plasma was approximately 200 ng/mL four days after
transfection. On day 5, PDGFR/Fc gene transfer signifi-
cantly reduced the number of proliferating cell nuclear
FUTURE PERSPECTIVES AND CONCLUSIONS
antigen-positive cells and glomerular cell numbers. North-
We are concerned in clinical applications with theern blot analysis demonstrated that glomerular mRNA
question of safety of gene therapy. The risk of toxicity,levels of -smooth muscle actin, TGF-1, and type I
even if only a small, seems to be inevitable in presentcollagen were also suppressed by the PDGFR/Fc trans-
viral vectors. Electrotransfer of plasmids has great meritfection. We also observed a significant reduction in ma-
from the viewpoint of safety and low cost. The genetrix score in the transfected nephritic rats. These results
expression by plasmid expression vectors generally ter-suggest that gene therapy that manipulates PDGF action
minates in eight weeks to nine months, and no particularusing electroporation-mediated PDGFR/Fc gene trans-
side effects have been reported. Therefore, we believefer to the skeletal muscle might be useful for a therapy
that the electroporation is one of the promising ap-of mesangioproliferative glomerulonephritis. Taken to-
proaches to human gene therapy.gether, gene transfer of the soluble cytokine receptor
As mentioned previously in this article, two strategiesmay be applicable for human gene therapy using skeletal
are practical: skeletal muscle-targeting gene therapy andmuscle.
transplant kidney gene therapy. Given that the systemicSimilar results can be achieved in an experimental
delivery of the functional protein can serve for the ther-model of lupus nephritis mice. Lawson et al reported that
apy of renal diseases, skeletal muscle-targeting genemuscle targeting gene therapy with a plasmid encoding
therapy is a good application. Skeletal muscle-targetinga soluble receptor for interferon- (IFN), IFNR/Fc,
gene therapy is easy to perform, repeatable, and highlysignificantly reduced the serum level of IFNr and disease
efficient in generating the secreting protein. In addition,manifestations, including lupus nephritis [43].
it is less expensive than the administration of the purified
recombinant protein. The diverse range of secreted pro-
GENE ELECTROTRANSFER TO KIDNEY teins, such as  inhibitors, activators, or soluble receptors
can be realized by basic gene technology in the labora-We studied the possibility of transferring a foreign
gene into kidney by electroporation. First, we selectively tory and may be directly applicable to clinical use.
The transplant kidney is another target for gene ther-infused FITC-labeled oligodeoxy nucleotides (ODN)
into the left renal artery and clamped the left renal vein apy. The delivery of therapeutic genes ex vivo has been
shown to be feasible, reducing rejection of transplantedimmediately after infusion. Thereafter, the left kidney
was electroporated between a pair of tweezers-type elec- kidneys in an animal model. An adenoviral vector was
also used for gene therapy of the transplant kidney.trodes. Although the electrodes did not cover the overall
surface of the kidney, FITC-labeled ODNs were present Swenson showed that Fas ligand gene transfer to the
kidney improved allograft survival from acute rejectiondiffusely in all glomeruli, including upper or lower pole
in the transfected left kidneys. To confirm the transgene in the rat [44]. Chronic rejection may be a target for
gene therapy. Recently, Azuma et al reported that theexpression by gene electrotransfer, X-gal staining was
performed on isolated glomeruli four days after transfer fibrotic change in the kidney in an experimental model
of chronic rejection could be reduced by administrationof LacZ gene expression vector. -Galactosidase expres-
sion was observed in 75% of glomeruli [8]. To determine of hepatocyte growth factor (HGF), an antifibrotic growth
factor [45]. This fact suggests that the intervention forthe optimal parameters of the electric field intensity,
we transfected a luciferase reporter gene at 25 to 125 early fibrosis by gene therapy can be applicable to the
therapy of chronic rejection. If gene transfer could beelectrode voltages. The luciferase activity tended to be
increased in accordance with voltage. On histological achieved by a nonviral vector, the feasibility of gene trans-
fer to the transplant kidney might be improved becauseexamination, we observed little harmful effect on treated
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